Phase 2 PTSD Trial, Recruiting NCT05441280 Sponsor: VA Office of Research and Development Condition: PTSD
Back to Ptsd

Phase 2 PTSD Trial, Recruiting

NCT05441280
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a Veteran between 18 and 64 years old (male or female)
  • You have chronic insomnia, meaning you have trouble falling asleep, staying asleep, or waking too early at least 3 nights per week for 3 or more months, and it affects your daytime functioning
  • Your insomnia is rated as moderate or severe based on a standard questionnaire (score of 15 or higher on the Insomnia Severity Index)
  • You have significant PTSD symptoms based on a standard checklist (score of 33 or higher on the PCL-5)
  • You are willing and able to follow all parts of the study
  • You agree not to start any new separate treatment programs for insomnia, PTSD, or other mental health conditions while in the study
  • If you are a woman who could become pregnant and are sexually active, you agree to use an approved form of birth control starting 30 days before the study drug and until 30 days after your last dose (acceptable methods include hormonal contraceptives or a non-hormonal IUD)
  • You are allowed to continue taking certain antidepressants or other approved psychiatric medications, as long as the dose has been stable for at least 1 month before joining

Who may not be able to join:

  • You have been diagnosed with, or have a history of, schizophrenia, schizoaffective disorder, or bipolar disorder
  • You are currently having thoughts of harming yourself or others that require immediate crisis help
  • You currently have a moderate or severe problem with alcohol, cannabis, or other substance use
  • You have a history of moderate or severe traumatic brain injury, stroke, epilepsy, multiple sclerosis, or similar neurological conditions
  • You drink large amounts of caffeine late in the day (for example, caffeinated drinks after 6:00 PM, 3 or more times a week) in a way that the study team believes is worsening your insomnia
  • You use tobacco close to bedtime in a way that the study team believes is affecting your sleep or would interfere with a sleep study
  • You have been diagnosed with certain other sleep disorders (such as restless legs syndrome, narcolepsy, or sleepwalking disorder) that could make it hard to accurately assess your insomnia (confirm with trial site)
  • You have been diagnosed with moderate to severe sleep apnea (a breathing problem during sleep), defined by a specific test score
  • A screening questionnaire suggests you are at high risk for moderate to severe sleep apnea
  • A sleep study done during screening shows signs of significant sleep apnea or other sleep problems
  • Your heart's electrical activity (measured by an ECG) shows an abnormally long interval (QTc over 470 ms for men or 480 ms for women)
  • You have recently been in therapy specifically for insomnia or PTSD (such as CBT-I, prolonged exposure, or cognitive processing therapy) within 1 week before joining, in a way that may affect study results
  • You have a significant ongoing health condition affecting your heart, lungs, stomach, kidneys, liver, or nervous system that could affect your safety or the study results
  • You are currently pregnant or breastfeeding
  • You are a woman who could become pregnant and are not using an approved form of birth control
  • You have a heart condition that puts you at risk for a dangerous irregular heartbeat (such as a condition called torsades de pointes or a naturally prolonged QT interval)
  • You are currently taking sleeping aids or sedating medications at bedtime (such as melatonin, zolpidem, benzodiazepines, trazodone, antihistamines, opioids, and others) — these must be stopped at least 1 week before joining
  • You are taking certain antipsychotic or antidepressant medications (such as quetiapine, olanzapine, mirtazapine, or trazodone) — these must be stopped at least 1 week before joining
  • You are taking certain strong medications that could significantly raise or lower the level of the study drug in your body (confirm with trial site for specific medications)
  • You are taking certain medications known to affect heart rhythm, including some heart medications, antipsychotics, and antibiotics (confirm with trial site for specific medications)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Melissa B Jones, MD, Michael E. DeBakey VA Medical Center, Houston, TX

Phone: (713) 794-1414

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
28 December 2023
Est. completion
12 July 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Insomnia Severity Index (ISI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov